Medicines widely used to treat diabetes, infections, pain and digestive disorders will cost 5-40 per cent less with immediate effect

Shares of the bank gained 3.30 per cent to settle at Rs 552.90 on the BSE. During the day, it surged 4.79 per cent to Rs 560.90.

The cash flows improvement would be based on a lot of multitude factors and macro development as well and improvement in macro factors as w...

Q4 when the discretionary budgeting decisions start firming up and clearly both these quarters traditionally weak quarters for the entire s...

At 11:00 a.m.; the stock was at Rs 626.50, down 0.65 per cent, on the BSE. It fell 1.43 per cent to touch intraday low of Rs 621.55 in trad...

This is the largest acquisition for Tech Mahindra and is expected to close by 4QFY2015. It will be financed through cash.

"We would probably wait for corrections on this stock as well because our belief is that at 10 times forward most of the positives from an ...

Incidentally from the midcap pharma space, Dishman Pharma is what we are liking. The stock has disappointed in terms of EBITDA margins in t...

We are liking from this space again has run up. We have recommended quite a few stocks in this space MM Forging, LG Balakrishna.

"Specifically companies like Motherson Sumi where utilisation levels are improving, new plants being put in that will drive the margins."

Goodyear has shown good amount of volume growth and we are expecting the sales growth to be quite robust going forward.

"The prices have been fixed / revised in respect of 43 formulation packs, both ceiling and retail price packs, under DPCO, 2013," NPPA said.

"Implementing policies thick and fast is a tough thing to do. So, one needs to give the government a little bit more time to formulate them...

HDFC has breached its FII limits and the FIPB approval for enhancing their limits would be a key trigger for the stock going forward.

There could be 100-200-point move on the outside with the kind of flows we are witnessing but clearly, one should have stock specific actio...

Lupin reported a net profit of Rs 553 cr for the quarter ended March 204, up 35.5%, from Rs 408 cr in the corresponding quarter last fiscal.

Shares of Ranbaxy Laboratories today settled for the day with losses of 1.51 %, pursuant to which the market capitalisation eroded by Rs 43...